Isoprenoids and Alzheimer's disease: A complex relationship

Neurobiology of Disease

Volumn 22, Issue 2, 2006, Pages 209-222

  Cole, S L ^a   Vassar, R ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

A ; Alzheimer's disease; APP metabolism; Cholesterol; Isoprenoids; Neuroinflammation; Statins; Tau

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; BETA SECRETASE; GAMMA SECRETASE; GERANYLTRANSFERASE; GUANOSINE TRIPHOSPHATASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; MEVALONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; ASTROCYTE; ATHEROSCLEROSIS; CELL FUNCTION; CHOLESTEROL DIET; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; GLIA; HUMAN; HYPERCHOLESTEROLEMIA; LOW DRUG DOSE; MOLECULAR MECHANICS; NERVE CELL NECROSIS; NERVE CELL PLASTICITY; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DEGRADATION; PROTEIN MODIFICATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; REVIEW; RISK FACTOR;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; CHOLESTEROL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEUROFIBRILLARY TANGLES; PROTEIN ISOPRENYLATION; SENILE PLAQUES; TERPENES;

EID: 33646137779     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2005.11.007     Document Type: Review

References (138)

1. Abad-Rodriguez J., Ledesma M.D., Craessaerts K., Perga S., Medina M., Delacourte A., Dingwall C., De Strooper B., and Dotti C.G. Neuronal membrane cholesterol loss enhances amyloid peptide generation. J. Cell Biol. 167 (2004) 953-960
2. Adamson P., Marshall C.J., Hall A., and Tilbrook P.A. Post-translational modifications of p21rho proteins. J. Biol. Chem. 267 (1992) 20033-20038
3. Adamson P., Paterson H.F., and Hall A. Intracellular localization of the P21rho proteins. J. Cell Biol. 119 (1992) 617-627
4. Alsop D.C., Detre J.A., and Grossman M. Assessment of cerebral blood flow in Alzheimer's disease by spin-labeled magnetic resonance imaging. Ann. Neurol. 47 (2000) 93-100
5. Anthony J.C., Breitner J.C., Zandi P.P., Meyer M.R., Jurasova I., Norton M.C., and Stone S.V. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study. Neurology 54 (2000) 2066-2071
6. Arelin K., Kinoshita A., Whelan C.M., Irizarry M.C., Rebeck G.W., Strickland D.K., and Hyman B.T. LRP and senile plaques in Alzheimer's disease: colocalization with apolipoprotein E and with activated astrocytes. Brain Res. Mol. Brain Res. 104 (2002) 38-46
7. Arendt T. Neurodegeneration and plasticity. Int. J. Dev. Neurosci. 22 (2004) 507-514
8. Bales K.R., Verina T., Cummins D.J., Du Y., Dodel R.C., Saura J., Fishman C.E., DeLong C.A., Piccardo P., Petegnief V., Ghetti B., and Paul S.M. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 15233-15238
9. Ballabh P., Braun A., and Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol. Dis. 16 (2004) 1-13
10. Baron R., Fourcade E., Lajoie-Mazenc I., Allal C., Couderc B., Barbaras R., Favre G., Faye J.C., and Pradines A. RhoB prenylation is driven by the three carboxyl-terminal amino acids of the protein: evidenced in vivo by an anti-farnesyl cysteine antibody. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 11626-11631
11. Benjannet S., Elagoz A., Wickham L., Mamarbachi M., Munzer J.S., Basak A., Lazure C., Cromlish J.A., Sisodia S., Checler F., Chretien M., and Seidah N.G. Post-translational processing of beta-secretase (beta-amyloid-converting enzyme) and its ectodomain shedding. The pro- and transmembrane/cytosolic domains affect its cellular activity and amyloid-beta production. J. Biol. Chem. 276 (2001) 10879-10887
12. Bi X., Baudry M., Liu J., Yao Y., Fu L., Brucher F., and Lynch G. Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia. J. Biol. Chem. 279 (2004) 48238-48245
13. Billings L.M., Oddo S., Green K.N., McGaugh J.L., and Laferla F.M. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45 (2005) 675-688
14. Bishop A.L., and Hall A. Rho GTPases and their effector proteins. Biochem. J. 348 (2000) 241-255
15. Blumenstein L., and Ahmadian M.R. Models of the cooperative mechanism for Rho effector recognition: implications for RhoA-mediated effector activation. J. Biol. Chem. 279 (2004) 53419-55326
16. Bodovitz S., and Klein W.L. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J. Biol. Chem. 271 (1996) 4436-4440
17. Botti R.E., Triscari J., Pan H.Y., and Zayat J. Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin. Neuropharmacol. 14 (1991) 256-261
18. Brazil M.I., Chung H., and Maxfield F.R. Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer's disease amyloid fibrils by microglia. J. Biol. Chem. 275 (2000) 16941-16947
19. Brown M.S., and Goldstein J.L. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J. Lipid Res. 21 (1980) 505-517
20. Burns M., Gaynor K., Olm V., Mercken M., LaFrancois J., Wang L., Mathews P.M., Noble W., Matsuoka Y., and Duff K. Presenilin redistribution associated with aberrant cholesterol transport enhances beta-amyloid production in vivo. J. Neurosci. 23 (2003) 5645-5649
21. Busciglio J., Pelsman A., Wong C., Pigino G., Yuan M., Mori H., and Yankner B.A. Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron 33 (2002) 677-688
22. Cataldo A.M., Petanceska S., Terio N.B., Peterhoff C.M., Durham R., Mercken M., Mehta P.D., Buxbaum J., Haroutunian V., and Nixon R.A. Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome. Neurobiol. Aging 25 (2004) 1263-1272
23. Cole S.L., Grudzien A., Manhart I.O., Kelly B.L., Oakley H., and Vassar R. Statins cause intracellular accumulation of amyloid precursor protein, beta-secretase-cleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanism. J. Biol. Chem. 280 (2005) 18755-18770
24. Collier F.M., Gregorio-King C.C., Gough T.J., Talbot C.D., Walder K., and Kirkland M.A. Identification and characterization of a lymphocytic Rho-GTPase effector: rhotekin-2. Biochem. Biophys. Res. Commun. 324 (2004) 1360-1369
25. Cordle A., and Landreth G. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses. J. Neurosci. 25 (2005) 299-307
26. Cordle A., Koenigsknecht-Talboo J., Wilkinson B., Limpert A., and Landreth G. Mechanisms of statin-mediated inhibition of small G-protein function. J. Biol. Chem. 280 (2005) 34202-34209
27. Cox A.D., and Der C.J. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?. Biochim. Biophys. Acta 1333 (1997) F51-F71
28. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., and Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 8850-8855
29. Dolev I., and Michaelson D.M. A nontransgenic mouse model shows inducible amyloid-beta (Abeta) peptide deposition and elucidates the role of apolipoprotein E in the amyloid cascade. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 13909-13914
30. Du W., Lebowitz P.F., and Prendergast G.C. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol. Cell. Biol. 19 (1999) 1831-1840
31. Dumanchin C., Czech C., Campion D., Cuif M.H., Poyot T., Martin C., Charbonnier F., Goud B., Pradier L., and Frebourg T. Presenilins interact with Rab11, a small GTPase involved in the regulation of vesicular transport. Hum. Mol. Genet. 8 (1999) 1263-1269
32. Eckert G.P., Kirsch C., and Mueller W.E. Differential effects of lovastatin treatment on brain cholesterol levels in normal and apoE-deficient mice. NeuroReport 12 (2001) 883-887
33. Edlund C., Soderberg M., and Kristensson K. Isoprenoids in aging and neurodegeneration. Neurochem. Int. 25 (1994) 35-38
34. Ehehalt R., Keller P., Haass C., Thiele C., and Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160 (2003) 113-123
35. Fassbender K., Simons M., Bergmann C., Stroick M., Lutjohann D., Keller P., Runz H., Kuhl S., Bertsch T., von Bergmann K., Hennerici M., Beyreuther K., and Hartmann T. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 5856-5861
36. Fassbender K., Stroick M., Bertsch T., Ragoschke A., Kuehl S., Walter S., Walter J., Brechtel K., Muehlhauser F., Von Bergmann K., and Lutjohann D. Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology 59 (2002) 1257-1258
37. Faust J.R., Brown M.S., and Goldstein J.L. Synthesis of delta 2-isopentenyl tRNA from mevalonate in cultured human fibroblasts. J. Biol. Chem. 255 (1980) 6546-6548
38. Foster R., Hu K.Q., Lu Y., Nolan K.M., Thissen J., and Settleman J. Identification of a novel human Rho protein with unusual properties: GTPase deficiency and in vivo farnesylation. Mol. Cell. Biol. 16 (1996) 2689-2699
39. Fuse M., Tanaka T., Shibata T., Yoshida T., Noguchi Y., Misawa N., Yasuda T., Saito Y., Kohn L.D., and Tatsuno I. Regulation of geranylgeranyl pyrophosphate synthase in the proliferation of rat FRTL-5 cells: involvement of both cAMP-PKA and PI3-AKT pathways. Biochem. Biophys. Res. Commun. 315 (2004) 1147-1153
40. Galbete J.L., Martin T.R., Peressini E., Modena P., Bianchi R., and Forloni G. Cholesterol decreases secretion of the secreted form of amyloid precursor protein by interfering with glycosylation in the protein secretory pathway. Biochem. J. 348 (2000) 307-313
41. Gibbs J.B., and Oliff A. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu. Rev. Pharmacol. Toxicol. 37 (1997) 143-166
42. Glenner G.G., and Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120 (1984) 885-890
43. Goldstein J.L., and Brown M.S. Regulation of the mevalonate pathway. Nature 343 (1990) 425-430
44. Gong Y., Chang L., Viola K.L., Lacor P.N., Lambert M.P., Finch C.E., Krafft G.A., and Klein W.L. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 10417-10422
45. Gonzalez R.G., Fischman A.J., Guimaraes A.R., Carr C.A., Stern C.E., Halpern E.F., Growdon J.H., and Rosen B.R. Functional MR in the evaluation of dementia: correlation of abnormal dynamic cerebral blood volume measurements with changes in cerebral metabolism on positron emission tomography with fludeoxyglucose F 18. Am. J. Neuroradiol. 16 (1995) 1763-1770
46. Gouras G.K., Tsai J., Naslund J., Vincent B., Edgar M., Checler F., Greenfield J.P., Haroutunian V., Buxbaum J.D., Xu H., Greengard P., and Relkin N.R. Intraneuronal Abeta42 accumulation in human brain. Am. J. Pathol. 156 (2000) 15-20
47. Grabowska D., Karst F., and Szkopinska A. Effect of squalene synthase gene disruption on synthesis of polyprenols in Saccharomyces cerevisiae. FEBS Lett. 434 (1998) 406-408
48. Guo L., LaDu M.J., and Van Eldik L.J. A dual role for apolipoprotein e in neuroinflammation: anti- and pro-inflammatory activity. J. Mol. Neurosci. 23 (2004) 205-212
49. Gylling H. Cholesterol metabolism and its implications for therapeutic interventions in patients with hypercholesterolaemia. Int. J. Clin. Pract. 58 (2004) 859-866
50. Haley R.W., and Dietschy J.M. Is there a connection between the concentration of cholesterol circulating in plasma and the rate of neuritic plaque formation in Alzheimer disease?. Arch. Neurol. 57 (2000) 1410-1412
51. Harris G.J., Lewis R.F., Satlin A., English C.D., Scott T.M., Yurgelun-Todd D.A., and Renshaw P.F. Dynamic susceptibility contrast MR imaging of regional cerebral blood volume in Alzheimer disease: a promising alternative to nuclear medicine. Am. J. Neuroradiol. 19 (1998) 1727-1732
52. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
53. Hoglund K., Wiklund O., Vanderstichele H., Eikenberg O., Vanmechelen E., and Blennow K. Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. Arch. Neurol. 61 (2004) 333-337
54. in 't Veld B.A., Launer L.J., Hoes A.W., Ott A., Hofman A., Breteler M.M., and Stricker B.H. NSAIDs and incident Alzheimer's disease. The Rotterdam Study. Neurobiol. Aging 19 (1998) 607-611
55. Jarvik G.P., Wijsman E.M., Kukull W.A., Schellenberg G.D., Yu C., and Larson E.B. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 45 (1995) 1092-1096
56. Jick H., Zornberg G.L., Jick S.S., Seshadri S., and Drachman D.A. Statins and the risk of dementia. Lancet 356 (2000) 1627-1631
57. Jin L.W., Maezawa I., Vincent I., and Bird T. Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities. Am. J. Pathol. 164 (2004) 975-985
58. Kaibuchi K., Kuroda S., and Amano M. Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells. Annu. Rev. Biochem. 68 (1999) 459-486
59. Kalback W., Esh C., Castano E.M., Rahman A., Kokjohn T., Luehrs D.C., Sue L., Cisneros R., Gerber F., Richardson C., Bohrmann B., Walker D.G., Beach T.G., and Roher A.E. Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease. Neurol. Res. 26 (2004) 525-539
60. Kametani F., Usami M., Tanaka K., Kume H., and Mori H. Mutant presenilin (A260V) affects Rab8 in PC12D cell. Neurochem. Int. 44 (2004) 313-320
61. Keller P., and Simons K. Cholesterol is required for surface transport of influenza virus hemagglutinin. J. Cell Biol. 140 (1998) 1357-1367
62. Kivipelto M., Helkala E.L., Laakso M.P., Hanninen T., Hallikainen M., Alhainen K., Iivonen S., Mannermaa A., Tuomilehto J., Nissinen A., and Soininen H. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann. Intern. Med. 137 (2002) 149-155
63. Klein W.L., Stine W.B.J., and Teplow D.B. Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol. Aging 25 (2004) 569-580
64. Kojro E., Gimpl G., Lammich S., Marz W., and Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 5815-5820
65. Kolsch H., Ptok U., Mohamed I., Schmitz S., Rao M.L., Maier W., and Heun R. Association of the C766T polymorphism of the low-density lipoprotein receptor-related protein gene with Alzheimer's disease. Am. J. Med. Genet. 121 (2003) 128-130
66. Kukar T., Murphy M.P., Eriksen J.L., Sagi S.A., Weggen S., Smith T.E., Ladd T., Khan M.A., Kache R., Beard J., Dodson M., Merit S., Ozols V.V., Anastasiadis P.Z., Das P., Fauq A., Koo E.H., and Golde T.E. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat. Med. 11 (2005) 545-550
67. Kumar A.P., and Reynolds W.F. Statins downregulate myeloperoxidase gene expression in macrophages. Biochem. Biophys. Res. Commun. 331 (2005) 442-451
68. Kumar B., Andreatta C., Koustas W.T., Cole W.C., Edwards-Prasad J., and Prasad K.N. Mevastatin induces degeneration and decreases viability of cAMP-induced differentiated neuroblastoma cells in culture by inhibiting proteasome activity, and mevalonic acid lactone prevents these effects. J. Neurosci. Res. 68 (2002) 627-635
69. Kuo Y.M., Emmerling M.R., Vigo-Pelfrey C., Kasunic T.C., Kirkpatrick J.B., Murdoch G.H., Ball M.J., and Roher A.E. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J. Biol. Chem. 271 (1996) 4077-4081
70. LaFerla F.M., Tinkle B.T., Bieberich C.J., Haudenschild C.C., and Jay G. The Alzheimer's A beta peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nat. Genet. 9 (1995) 21-30
71. Lebowitz P.F., Du W., and Prendergast G.C. Prenylation of RhoB is required for its cell transforming function but not its ability to activate serum response element-dependent transcription. J. Biol. Chem. 272 (1997) 16093-16095
72. Lee M., You H.J., Cho S.H., Woo C.H., Yoo M.H., Joe E.H., and Kim J.H. Implication of the small GTPase Rac1 in the generation of reactive oxygen species in response to beta-amyloid in C6 astroglioma cells. Biochem. J. 366 (2002) 937-943
73. Liao J.K., and Laufs U. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 89-118
74. Ling S., Wu Y., Zheng J., Linden J., and Holoshitz J. Genoprotective pathways: II. Attenuation of oxidative DNA damage by isopentenyl diphosphate. Mutat. Res. 554 (2004) 33-43
75. Liu A., Du W., Liu J.P., Jessell T.M., and Prendergast G.C. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Mol. Cell. Biol. 20 (2000) 6105-6113
76. Luo Z.G., Je H.S., Wang Q., Yang F., Dobbins G.C., Yang Z.H., Xiong W.C., Lu B., and Mei L. Implication of geranylgeranyltransferase I in synapse formation. Neuron 40 (2003) 703-717
77. Magrane J., Smith R.C., Walsh K., and Querfurth H.W. Heat shock protein 70 participates in the neuroprotective response to intracellularly expressed beta-amyloid in neurons. J. Neurosci. 24 (2004) 1700-1706
78. Marks N., and Berg M.J. APP processing enzymes (secretases) as therapeutic targets: insights from the use of transgenics (Tgs) and transfected cells. Neurochem. Res. 28 (2003) 1049-1062
79. Masters C.L., Multhaup G., Simms G., Pottigiesser J., Martins R.N., and Beyreuther K. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J. 4 (1985) 2757-2763
80. Meske V., Albert F., Richter D., Schwarze J., and Ohm T.G. Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease. Eur. J. Neurosci. 17 (2003) 93-102
81. Mo H., and Elson C.E. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp. Biol. Med. 229 (2004) 567-585
82. Monick M.M., Powers L.S., Butler N.S., and Hunninghake G.W. Inhibition of Rho family GTPases results in increased TNF-alpha production after lipopolysaccharide exposure. J. Immunol. 171 (2003) 2625-2630
83. Mori C., Spooner E.T., Wisniewsk K.E., Wisniewski T.M., Yamaguch H., Saido T.C., Tolan D.R., Selkoe D.J., and Lemere C.A. Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid 9 (2002) 88-102
84. Naidu A., Xu Q., Catalano R., and Cordell B. Secretion of apolipoprotein E by brain glia requires protein prenylation and is suppressed by statins. Brain Res. 958 (2002) 100-111
85. Nishimura M., Tanaka T., Yasuda T., Kurakata S., Kitagawa M., Yamada K., Saito Y., and Hirai A. Collagen secretion and growth of mesangial cells require geranylgeranylpyrophosphate. Kidney Int. 55 (1999) 520-528
86. Papassotiropoulos A., Streffer J.R., Tsolaki M., Schmid S., Thal D., Nicosia F., Iakovidou V., Maddalena A., Lutjohann D., Ghebremedhin E., Hegi T., Pasch T., Traxler M., Bruhl A., Benussi L., Binetti G., Braak H., Nitsch R.M., and Hock C. Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch. Neurol. 60 (2003) 29-35
87. Papassotiropoulos A., Wollmer M.A., Tsolaki M., Brunner F., Molyva D., Lutjohann D., Nitsch R.M., and Hock C. A cluster of cholesterol-related genes confers susceptibility for Alzheimer's disease. J. Clin. Psychiatry 66 (2005) 940-947
88. Pedrini S., Carter T.L., Prendergast G., Petanceska S., Ehrlich M.E., and Gandy S. Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. PLoS Med. 2 (2005) e18
89. Pilpel Y., and Segal M. Activation of PKC induces rapid morphological plasticity in dendrites of hippocampal neurons via Rac and Rho-dependent mechanisms. Eur. J. Neurosci. 19 (2004) 3151-3164
90. Puglielli L., Konopka G., Pack-Chung E., Ingano L.A., Berezovska O., Hyman B.T., Chang T.Y., Tanzi R.E., and Kovacs D.M. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat. Cell Biol. 3 (2001) 905-912
91. Rao S., Porter D.C., Chen X., Herliczek T., Lowe M., and Keyomarsi K. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 7797-7802
92. Reddy P.H., Mani G., Park B.S., Jacques J., Murdoch G., Whetsell W.J., Kaye J., and Manczak M. Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. J. Alzheimer's Dis. 7 (2005) 103-117
93. Ridley A.J. Rho proteins: linking signaling with membrane trafficking. Traffic 2 (2001) 303-310
94. Rodriguez-Viciana P., Sabatier C., and McCormick F. Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol. Cell. Biol. 24 (2004) 4943-4954
95. Runz H., Rietdorf J., Tomic I., de Bernard M., Beyreuther K., Pepperkok R., and Hartmann T. Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. J. Neurosci. 22 (2002) 1679-1689
96. Santos Da Silva J., Schubert V., and Dotti C.G. RhoA, Rac1, and cdc42 intracellular distribution shift during hippocampal neuron development. Mol. Cell. Neurosci. 27 (2004) 1-7
97. Scheffler I.E. Metabolic pathways inside mitochondria. Mitochondria (1999), Wiley-Liss, Inc. 246-272
98. Schenk D.B., and Yednock T. The role of microglia in Alzheimer's disease: friend or foe?. Neurobiol. Aging 23 (2002) 677-679
99. Scheper W., Zwart R., and Baas F. Rab6 membrane association is dependent of Presenilin 1 and cellular phosphorylation events. Brain Res. Mol. Brain Res. 122 (2004) 17-23
100. Sebti S.M., and Hamilton A.D. Inhibition of Ras prenylation: a novel approach to cancer chemotherapy. Pharmacol. Ther. 74 (1997) 103-114
101. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81 (2001) 741-766
102. Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., Ford I., Gaw A., Hyland M., Jukema J.W., Kamper A.M., Macfarlane P.W., Meinders A.E., Norrie J., Packard C.J., Perry I.J., Stott D.J., Sweeney B.J., Twomey C., and Westendorp R.G. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
103. Shimohama S., Kamiya S., Taniguchi T., Sumida Y., and Fujimoto S. Differential involvement of small G proteins in Alzheimer's disease. Int. J. Mol. Med. 3 (1999) 597-600
104. Simons M., Keller P., De Strooper B., Beyreuther K., Dotti C.G., and Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 6460-6464
105. Sisodia S.S., Kim S.H., and Thinakaran G. Function and dysfunction of the presenilins. Am. J. Hum. Genet. 65 (1999) 7-12
106. Skoog I., and Gustafson D. Hypertension and related factors in the etiology of Alzheimer's disease. Ann. N. Y. Acad. Sci. 977 (2002) 29-36
107. Skoog I., Lernfelt B., Landahl S., Palmertz B., Andreasson L.A., Nilsson L., Persson G., Oden A., and Svanborg A. 15-year longitudinal study of blood pressure and dementia. Lancet 347 (1996) 1141-1145
108. Skovronsky D.M., Doms R.W., and Lee V.M. Detection of a novel intraneuronal pool of insoluble amyloid beta protein that accumulates with time in culture. J. Cell Biol. 141 (1998) 1031-1039
109. Skovronsky D.M., Moore D.B., Milla M.E., Doms R.W., and Lee V.M. Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-golgi network. J. Biol. Chem. 275 (2000) 2568-2575
110. Solski P.A., Helms W., Keely P.J., Su L., and Der C.J. RhoA biological activity is dependent on prenylation but independent of specific isoprenoid modification. Cell Growth Differ. 13 (2002) 363-373
111. Soneira C.F., and Scott T.M. Severe cardiovascular disease and Alzheimer's disease: senile plaque formation in cortical areas. Clin. Anat. 9 (1996) 118-127
112. Sparks D.L. Intraneuronal beta-amyloid immunoreactivity in the CNS. Neurobiol. Aging 17 (1996) 291-299
113. Sparks D.L., Hunsaker J.C.R., Scheff S.W., Kryscio R.J., Henson J.L., and Markesbery W.R. Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol. Aging 11 (1990) 601-607
114. Sparks D.L., Scheff S.W., Hunsaker J.C., Liu H., Landers T., and Gross D.R. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. 126 (1994) 88-94
115. Sparks D.L., Sabbagh M.N., Connor D.J., Lopez J., Launer L.J., Browne P., Wasser D., Johnson-Traver S., Lochhead J., and Ziolwolski C. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch. Neurol. 62 (2005) 753-757
116. Suopanki J., Tyynela J., Baumann M., and Haltia M. Palmitoyl-protein thioesterase, an enzyme implicated in neurodegeneration, is localized in neurons and is developmentally regulated in rat brain. Neurosci. Lett. 265 (1999) 53-56
117. Takahashi R.H., Milner T.A., Li F., Nam E.E., Edgar M.A., Yamaguchi H., Beal M.F., Xu H., Greengard P., and Gouras G.K. International Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am. J. Pathol. 161 (2002) 1869-1879
118. Takahashi R.H., Almeida C.G., Kearney P.F., Yu F., Lin M.T., Milner T.A., and Gouras G.K. Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J. Neurosci. 24 (2004) 3592-3599
119. Takai Y., Sasaki T., and Matozaki T. Small GTP-binding proteins. Physiol. Rev. 81 (2001) 153-208
120. Tatsuno I., Tanaka T., Oeda T., Yasuda T., Kitagawa M., Saito Y., and Hirai A. Geranylgeranylpyrophosphate, a metabolite of mevalonate, regulates the cell cycle progression and DNA synthesis in human lymphocytes. Biochem. Biophys. Res. Commun. 241 (1997) 376-382
121. Terano T., Shiina T., Noguchi Y., Tanaka T., Tatsuno I., Saito Y., Yasuda T., Kitagawa M., and Hirai A. Geranylgeranylpyrophosphate plays a key role for the G1 to S transition in vascular smooth muscle cells. J. Atheroscler. Thromb. 5 (1998) 1-6
122. Urano Y., Hayashi I., Isoo N., Reid P.C., Shibasaki Y., Noguchi N., Tomita T., Iwatsubo T., Hamakubo T., and Kodama T. Association of active gamma-secretase complex with lipid rafts. J. Lipid Res. 46 (2005) 904-912
123. Vassar R. BACE1: the beta-secretase enzyme in Alzheimer's disease. J. Mol. Neurosci. 23 (2004) 105-114
124. Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., Teplow D.B., Ross S., Amarante P., Loeloff R., Luo Y., Fisher S., Fuller J., Edenson S., Lile J., Jarosinski M.A., Biere A.L., Curran E., Burgess T., Louis J.-C., Collins F., Treanor J., Rogers G., and Citron M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286 (1999) 735-741
125. Vega G.L., Weiner M.F., Lipton A.M., Von Bergmann K., Lutjohann D., Moore C., and Svetlik D. Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch. Neurol. 60 (2003) 510-515
126. Vesa J., Hellsten E., Verkruyse L.A., Camp L.A., Rapola J., Santavuori P., Hofmann S.L., and Peltonen L. Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis. Nature 376 (1995) 584-587
127. Vetrivel K.S., Cheng H., Lin W., Sakurai T., Li T., Nukina N., Wong P.C., Xu H., and Thinakaran G. Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes. J. Biol. Chem. 279 (2004) 44945-44954
128. Vetrivel K.S., Cheng H., Kim S.H., Chen Y., Barnes N.Y., Parent A.T., Sisodia S.S., and Thinakaran G. Spatial segregation of gamma-secretase and substrates in distinct membrane domains. J. Biol. Chem. 280 (2005) 25892-25900
129. Vicent D., Maratos-Flier E., and Kahn C.R. The branch point enzyme of the mevalonate pathway for protein prenylation is overexpressed in the ob/ob mouse and induced by adipogenesis. Mol. Cell. Biol. 20 (2000) 2158-2166
130. Wheeler A.P., and Ridley A.J. Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility. Exp. Cell Res. 301 (2004) 43-49
131. Wierzbicki A.S., Poston R., and Ferro A. The lipid and non-lipid effects of statins. Pharmacol. Ther. 99 (2003) 95-112
132. Wolozin B. Cholesterol and the biology of Alzheimer's disease. Neuron 41 (2004) 7-10
133. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., and Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57 (2000) 1439-1443
134. Yamazaki T., Chang T.Y., Haass C., and Ihara Y. Accumulation and aggregation of amyloid beta-protein in late endosomes of Niemann-Pick type C cells. J. Biol. Chem. 276 (2001) 4454-4460
135. Younkin S.G. The role of Abeta 42 in Alzheimer's disease. J. Physiol. (Paris) 92 (1998) 289-292
136. Zandi P.P., Sparks D.L., Khachaturian A.S., Tschanz J., Norton M., Steinberg M., Welsh-Bohmer K.A., and Breitner J.C. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch. Gen. Psychiatry 62 (2005) 217-224
137. Zhang F.L., and Casey P.J. Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65 (1996) 241-269
138. Zhou Y., Su Y., Li B., Liu F., Ryder J.W., Wu X., Gonzalez-DeWhitt P.A., Gelfanova V., Hale J.E., May P.C., Paul S.M., and Ni B. Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science 302 (2003) 1215-1217